Breast Cancer Clinical Trials

Showing 81-100 of 2,749 trials

Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

NCT06617455

This phase II trial tests how well fezolinetant works in improving vasomotor symptoms (VMS) in breast cancer patients taking endocrine therapy (ET). Anti-hormone treatments are effective for lowering the risk of breast cancer but can cause bothersome VMS, such as hot flashes and night sweats. Fezolinetant inhibits the activity of the neurokinin type 3 receptor and has shown activity against VMS in postmenopausal women. Taking fezolinetant may work well at improving VMS in breast cancer patients taking ET.

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more

University of Michigan Rogel Cancer Center9 participantsStarted Oct 2024

Ann Arbor, Michigan, United States

RECRUITINGPHASE1

A Study of LY4175408 in Participants With Advanced Cancer

NCT07046923

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.

Carcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaEndometrial Neoplasms+2 more

Eli Lilly and Company240 participantsStarted Jul 2025

Stanford, California, United States • Orlando, Florida, United States • Sarasota, Florida, United States +21 more locations

Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

A Study of LY4175408 in Participants With Advanced Cancer

Related Searches

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial

Mobile Health for Adherence in Breast Cancer Patients

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Trial to Evaluate an Educational Video Series for Women in Breast Cancer Treatment

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

A Study of Surgery and Radiotherapy in People With Breast Cancer

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

3D Printed Breast Models in the Surgical Management of Breast Cancer

Gait Characteristics of Women With Breast Cancer-Related Lymphedema

Stereotactic Guided Biopsy and Cryoablation

Evaluation of Data Obtained From Three Common Imaging Techniques: Positron Emission Tomography (PET-CT), Breast Ultrasound, and Magnetic Resonance Imaging (MRI) After Neoadjuvant Chemotherapy in Patients With Breast Cancer

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy